RS57021B1 - Il-22 for use in treating microbial disorders - Google Patents

Il-22 for use in treating microbial disorders

Info

Publication number
RS57021B1
RS57021B1 RS20180324A RSP20180324A RS57021B1 RS 57021 B1 RS57021 B1 RS 57021B1 RS 20180324 A RS20180324 A RS 20180324A RS P20180324 A RSP20180324 A RS P20180324A RS 57021 B1 RS57021 B1 RS 57021B1
Authority
RS
Serbia
Prior art keywords
treating microbial
microbial disorders
disorders
treating
microbial
Prior art date
Application number
RS20180324A
Other languages
Serbian (sr)
Inventor
Alexander R Abbas
Dimitry M Danilenko
Sauvage Frederic J De
Nico P Ghilardi
Zora Modrusan
Wenjun Ouyang
Patricia A Valdez
Yan Zheng
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of RS57021B1 publication Critical patent/RS57021B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
RS20180324A 2007-11-07 2008-11-07 Il-22 for use in treating microbial disorders RS57021B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US98617007P 2007-11-07 2007-11-07
US1362007P 2007-12-13 2007-12-13
US1562007P 2007-12-20 2007-12-20
EP12169572.0A EP2514436B1 (en) 2007-11-07 2008-11-07 Il-22 for use in treating microbial disorders

Publications (1)

Publication Number Publication Date
RS57021B1 true RS57021B1 (en) 2018-05-31

Family

ID=40551983

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20180324A RS57021B1 (en) 2007-11-07 2008-11-07 Il-22 for use in treating microbial disorders

Country Status (26)

Country Link
US (4) US20090202475A1 (en)
EP (3) EP3360567A1 (en)
JP (3) JP5985150B2 (en)
KR (2) KR20160129099A (en)
CN (5) CN103142999A (en)
AU (1) AU2008323770B2 (en)
CA (1) CA2705007A1 (en)
CO (1) CO6280406A2 (en)
DK (1) DK2514436T3 (en)
ES (1) ES2662845T3 (en)
HK (2) HK1214137A1 (en)
HR (1) HRP20180445T1 (en)
HU (1) HUE038588T2 (en)
IL (2) IL205623A0 (en)
LT (1) LT2514436T (en)
MX (1) MX2010005108A (en)
NO (1) NO2514436T3 (en)
PH (1) PH12013501074A1 (en)
PL (1) PL2514436T3 (en)
PT (1) PT2514436T (en)
RS (1) RS57021B1 (en)
RU (1) RU2503460C2 (en)
SG (2) SG10202007210RA (en)
SI (1) SI2514436T1 (en)
WO (1) WO2009062102A2 (en)
ZA (1) ZA201003113B (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361968B (en) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 Use of interleukin-22 in treating fatty liver
EP2352762A1 (en) * 2008-11-03 2011-08-10 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
WO2011046616A2 (en) * 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
WO2011127344A2 (en) * 2010-04-08 2011-10-13 University Of Virginia Patent Foundation Method to detect and treat infectious or inflammatory diarrhea
CN102260343A (en) 2010-05-25 2011-11-30 健能隆医药技术（上海）有限公司 Application of recombinant human G-CSF dimer for treating nerve damage disease
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
EP2737905B1 (en) 2011-07-25 2019-09-11 Generon (Shanghai) Corporation Ltd. Use of g-csf dimer in preparation of medicament for treatment of neurodegenerative diseases
JP2015500482A (en) * 2011-12-05 2015-01-05 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Graphene-Biomolecular Bioelectronic Device
CN102559759A (en) * 2011-12-19 2012-07-11 西安交通大学医学院第一附属医院 HIP/PAP recombinant adenovirus and application thereof in resisting ulcerative colitis
CN103182072B (en) 2011-12-27 2017-05-03 健能隆医药技术（上海）有限公司 Application of interleukin-22 in treating and preventing nerve injuries and neurodegeneration diseases
KR101431324B1 (en) * 2012-08-20 2014-08-20 성균관대학교산학협력단 A pharmaceutical composition comprising a peptide WKYMVm for prevention and treatment of inflammatory bowel diseases
US9314504B2 (en) * 2013-03-14 2016-04-19 Taipei Medical University Use of members of IL-10 cytokine family
WO2014139182A1 (en) 2013-03-15 2014-09-18 Shenzhen Hightide Biopharmaceutical, Ltd. Compositions and methods of using islet neogenesis peptides and analogs thereof
BR112015023140A8 (en) 2013-03-15 2018-01-23 Genentech Inc fusion proteins, fusion protein manufacturing method, compositions, nucleic acid, vector, host cell, methods of producing a fusion protein, treating inflammatory bowel disease, inhibiting microbial infection, treating kidney injury , to accelerate or improve healing, to prevent or treat a cardiovascular condition, to treat metabolic syndrome, and to treat endotoxemia.
WO2015054386A1 (en) 2013-10-08 2015-04-16 Georgia State University Research Foundation, Inc Compositions including il-18 and il-22 and their use in anti-viral therapies
CN103554267A (en) * 2013-10-15 2014-02-05 山西农业大学 Fusion protein with anti-bacterial function, its construction method and application
JP5515104B1 (en) * 2013-10-25 2014-06-11 独立行政法人農業・食品産業技術総合研究機構 Mycobacterial growth promoter, method for culturing mycobacteria by adding it, and culture medium for acid-fast bacterium containing the same
CN104623637A (en) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Application of IL-22 dimer in preparation of intravenous injection drugs
AU2014346554B2 (en) * 2013-11-07 2020-06-04 Evive Biotechnology (Shanghai) Ltd Methods of use for IL-22 in the treatment of gastrointestinal graft vs. host disease
CN108976289B (en) * 2015-11-20 2021-06-18 深圳市南山区人民医院 Peptide fragment for preventing and treating enteropathogenic escherichia coli infection
EP3442562B1 (en) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd An il-22 dimer for use in treating necrotizing enterocolitis
AU2017266929B2 (en) * 2016-05-18 2023-05-11 Modernatx, Inc. Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
CN112004549A (en) * 2017-07-13 2020-11-27 国家健康与医学研究院 REG3 alpha for protecting oxygen sensitive gram positive bacteria
WO2022192419A2 (en) 2021-03-09 2022-09-15 Massachusetts Institute Of Technology Methods of treating inflammatory bowel disease (ibd) with anti- tnf-blockade
CN113304247B (en) * 2021-04-01 2024-03-19 上海市儿科医学研究所 Reg4 protein and application thereof in resisting salmonella enteritidis infection
CN114409758A (en) * 2022-01-24 2022-04-29 上海市儿科医学研究所 Application of Reg4 antibacterial peptide in treatment of pathogenic escherichia coli infection
CN114344451B (en) * 2022-01-25 2023-09-26 上海市肺科医院 Application of Reg4 antibacterial peptide in treatment of pseudomonas aeruginosa infectious pneumonia

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
JPS60500673A (en) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン Amino acid sequence with antigenic activity
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5683688A (en) 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
NZ215865A (en) 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド Modifications of or for denatured antibodies
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE135397T1 (en) 1988-09-23 1996-03-15 Cetus Oncology Corp CELL CULTIVATION MEDIUM FOR INCREASED CELL GROWTH, TO INCREASE THE LONGEVITY AND EXPRESSION OF THE PRODUCTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE102631T1 (en) 1988-11-11 1994-03-15 Medical Res Council CLONING OF IMMUNOGLOBULIN SEQUENCES FROM THE VARIABLE DOMAINS.
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
ATE144793T1 (en) 1989-06-29 1996-11-15 Medarex Inc BISPECIFIC REAGENTS FOR AIDS THERAPY
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
KR920702409A (en) 1989-10-24 1992-09-04 원본미기재 Oligonucleotide Analogues Having Novel Bindings
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
WO1992000329A1 (en) 1990-06-27 1992-01-09 Biogen, Inc. Surface complexed lymphotoxin
KR0149181B1 (en) 1990-06-29 1998-08-17 데이비드 알, 맥지 Melanin production by transformed microorganisms
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
WO1992009300A1 (en) 1990-11-21 1992-06-11 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69333807T2 (en) 1992-02-06 2006-02-02 Chiron Corp., Emeryville MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR
CA2140280A1 (en) 1992-08-17 1994-03-03 Avi J. Ashkenazi Bispecific immunoadhesins
JP3095175B2 (en) 1992-11-13 2000-10-03 アイデック ファーマシューティカルズ コーポレイション Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antigen for the treatment of B cell lymphoma
JPH08511420A (en) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド Body
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997038123A1 (en) 1996-04-05 1997-10-16 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
EP0942968B1 (en) 1996-12-03 2008-02-27 Amgen Fremont Inc. Fully human antibodies that bind EGFR
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
JP2002506353A (en) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド Methods and compositions for galactosylated glycoproteins
DE69840412D1 (en) 1997-10-31 2009-02-12 Genentech Inc METHODS AND COMPOSITIONS CONTAINING GLYCOPROTEIN GLYCOR FORMS
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
PT1071700E (en) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US20030003545A1 (en) * 1998-05-29 2003-01-02 Reinhard Ebner Interleukins-21 and 22
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
JP2002533726A (en) 1998-12-28 2002-10-08 サネシス ファーマシューティカルス インコーポレイテッド Identification of small organic molecule ligands for binding
PL209786B1 (en) 1999-01-15 2011-10-31 Genentech Inc Variant of mother polypeptide containing Fc region, polypeptide containing variant of Fc region with altered affinity of Fc gamma receptor binding (Fc R), polypeptide containing variant of Fc region with altered affinity of Fc gamma neonatal receptor binding (Fc Rn), composition, isolated nucleic acid, vector, host cell, method for obtaining polypeptide variant, the use thereof and method for obtaining region Fc variant
ES2569919T3 (en) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedure to control the activity of an immunofunctional molecule
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
WO2001029246A1 (en) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
US20030170823A1 (en) * 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
GB0024442D0 (en) * 2000-10-05 2000-11-22 Isis Innovation Genetic factors affecting the outcome of viral infections
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
BR0213761A (en) 2001-10-25 2005-04-12 Genentech Inc Compositions, pharmaceutical preparation, industrialized article, mammalian treatment method, host cell, method for producing a glycoprotein and use of the composition
FR2833011B1 (en) * 2001-12-04 2004-10-29 Univ Claude Bernard Lyon NOVEL PROTEIN WITH IL-6 INHIBITING ACTIVITY
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk Process for producing antibody composition
ATE503829T1 (en) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd CELL WITH REDUCED OR DELETED ACTIVITY OF A PROTEIN INVOLVED IN GDP-FUCOSE TRANSPORT
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
EP1499353A4 (en) 2002-04-15 2006-04-05 Human Genome Sciences Inc Antibodies that specifically bind to tl5
AU2003256299A1 (en) * 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HU227217B1 (en) 2002-12-16 2010-11-29 Genentech Inc Immunoglobulin variants and uses thereof
WO2004058307A1 (en) * 2002-12-18 2004-07-15 Wyeth Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
ATE490275T1 (en) * 2003-06-23 2010-12-15 Genetics Inst Llc ANTIBODIES TO INTERLEUKIN-22 AND USES THEREOF
EP1660632B1 (en) * 2003-08-01 2014-02-19 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
RS54450B1 (en) 2003-11-05 2016-06-30 Roche Glycart Ag Antigen binding molecules with increased fc receptor binding affinity and effector function
WO2005053742A1 (en) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Medicine containing antibody composition
US20050277593A1 (en) * 2004-05-24 2005-12-15 Washington University Therapeutic uses of Reg protein
RU2302460C1 (en) * 2005-11-02 2007-07-10 Институт цитологии и генетики Сибирского отделения Российской академии наук (СО РАН) RECOMBINANT PLASMID DNA pBi101-IL18 ENCODING HUMAN INTERLEUKIN-18 SYNTHESIS IN TRANSGENIC PLANTS
CA2652924A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17

Also Published As

Publication number Publication date
IL205623A0 (en) 2010-11-30
JP2011503102A (en) 2011-01-27
AU2008323770B2 (en) 2014-08-07
WO2009062102A3 (en) 2009-09-24
JP2015003924A (en) 2015-01-08
PH12013501074A1 (en) 2015-01-26
SG185972A1 (en) 2012-12-28
DK2514436T3 (en) 2018-03-12
CN101951945A (en) 2011-01-19
CN108815508A (en) 2018-11-16
RU2503460C2 (en) 2014-01-10
WO2009062102A2 (en) 2009-05-14
EP2514436A2 (en) 2012-10-24
RU2010122982A (en) 2011-12-20
EP3360567A1 (en) 2018-08-15
NO2514436T3 (en) 2018-05-19
EP2514436B1 (en) 2017-12-20
CN103142999A (en) 2013-06-12
LT2514436T (en) 2018-04-10
US20090202475A1 (en) 2009-08-13
CN102172395A (en) 2011-09-07
ES2662845T3 (en) 2018-04-10
HK1214137A1 (en) 2016-07-22
AU2008323770A1 (en) 2009-05-14
IL258730A (en) 2018-06-28
ZA201003113B (en) 2015-08-26
EP2514436A3 (en) 2013-01-16
SI2514436T1 (en) 2018-04-30
EP2217263A2 (en) 2010-08-18
CA2705007A1 (en) 2009-05-14
HK1259102A1 (en) 2019-11-22
CO6280406A2 (en) 2011-05-20
US20210338778A1 (en) 2021-11-04
AU2008323770A2 (en) 2010-12-09
PT2514436T (en) 2018-03-21
CN104888193A (en) 2015-09-09
JP5985150B2 (en) 2016-09-06
KR20100096137A (en) 2010-09-01
KR20160129099A (en) 2016-11-08
US20110280828A1 (en) 2011-11-17
US20130052159A1 (en) 2013-02-28
JP6266486B2 (en) 2018-01-24
HRP20180445T1 (en) 2018-04-20
SG10202007210RA (en) 2020-08-28
HUE038588T2 (en) 2018-10-29
KR101867606B1 (en) 2018-06-18
MX2010005108A (en) 2010-05-27
JP2016117760A (en) 2016-06-30
PL2514436T3 (en) 2018-06-29

Similar Documents

Publication Publication Date Title
HK1259102A1 (en) Amp for use in treating microbial disorders
HK1157410A1 (en) Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders
EP2124778A4 (en) Devices for treating the spine
EP2124777A4 (en) Devices for treating the spine
EP2212849A4 (en) Large block trading
ZA200908047B (en) Adjustable grinder
EP2106814A4 (en) Treatment device
GB0723874D0 (en) Dressing
IL205939A (en) Compounds for use in treating lysosomal disorders
ZA200905879B (en) Arabinoxylo-oligosaccharides in beer
GB2467710B (en) Methods for treating social disorders
AP2011005611A0 (en) Amide compounds useful in therapy.
EP2370008A4 (en) Rearchitecting the spine
GB0705923D0 (en) Dressing
PT2337573E (en) Whey for use in treating lymphocytopenia
PT2481407T (en) Compounds for use in treating cognitive disorders
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
EP2184770A4 (en) Polishing apparatus
GB2467860B (en) Adjustable noggings
EP2121785A4 (en) Sydnonimines - specific dopamine reuptake inhibitors and their use in treating dopamine related disorders
IL207906A0 (en) Treatment for ocular-related disorders
ZA201003587B (en) N-cycloalkylmethyl-2-aminothiazole-5-carboxamides for use in plant disease control
GB0718428D0 (en) Adjustable grinder
GB0714119D0 (en) Improvements in transistors
GB0705125D0 (en) Seating units